SCHEMBL7205673

SCHEMBL7205673

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3ccccc3F)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.39
MMP13 P45452 1/20 0.39
DPP4 P27487 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
RORC P51449 1/20 0.35
PAX8 Q06710 2/20 0.35
ACHE P22303 1/20 0.35
KDM2B Q8NHM5 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
F10 P00742 1/20 0.34
TMPRSS6 Q8IU80 1/20 0.34
ST14 Q9Y5Y6 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GHSR Q92847 1/20 0.34
PDE4B Q07343 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201014 0.88 SMN1; SMN2 (0.41) MMP1MMP13ALDH1A1GHSR
SCHEMBL7292292 0.88 AKR1C3 (0.45) MMP1MMP13DPP4DPP7KDM2B
SCHEMBL7204213 0.88 MMP13 (0.52) MMP1MMP13DPP4DPP7RORC
SCHEMBL7201540 0.86 ADAMTS4 (0.39) MMP1MMP13DPP4RORCMAPT
SCHEMBL7204539 0.86 MMP1 (0.40) MMP1MMP13DPP4DPP7PAX8
SCHEMBL7199674 0.83 MMP1 (0.42) MMP1MMP13ALDH1A1
SCHEMBL7202567 0.83 MMP13 (0.40) MMP1MMP13PAX8KDM2BALDH1A1
SCHEMBL7204066 0.82 ALDH1A1 (0.38) MMP1MMP13ALDH1A1
SCHEMBL7300738 0.82 MMP13 (0.48) MMP1MMP13ALDH1A1
SCHEMBL7202625 0.82 CCR6 (0.39) MMP1MMP13DPP4DPP7KDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885DPP4 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.